Improvement of Nail Psoriasis with Brodalumab in Phase 3 Trials

Mark G Lebwohl; Lawrence Green; Sylvia Hsu; Shipra Rastogi; Tina Lin; Radhakrishnan Pillai; Robert J Israel

doi:10.25251/skin.1.supp.98

Mark G Lebwohl
Lawrence Green
Sylvia Hsu
Shipra Rastogi
Tina Lin
Radhakrishnan Pillai
Robert J Israel

Keywords

nail, nail psoriasis, psoriasis, brodalumab, clinical trial

Abstract

Abstract Not Available

Poster PDF

Published

Oct 27, 2017

DOI https://doi.org/10.25251/skin.1.supp.98

How to Cite

Lebwohl, M. G., Green, L., Hsu, S., Rastogi, S., Lin, T., Pillai, R., & Israel, R. J. (2017). Improvement of Nail Psoriasis with Brodalumab in Phase 3 Trials. SKIN The Journal of Cutaneous Medicine, 1(3.1), s99. https://doi.org/10.25251/skin.1.supp.98

Issue

Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas

Section

Nail Unit Disorders

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Christopher Bunick, Neal Bhatia, James Del Rosso, Zoe Draelos, Lawrence Eichenfield, Leon Kircik, Mark Lebwohl, Melinda Gooderham, Lawrence Green, Adelaide Hebert, Ronald Vender, Matthew Zirwas, Eric Simpson, Linda Stein Gold, Melissa Seal, Scott Snyder, David Osborne, Patrick Burnett, Robert Higham, David Chu, David Berk, Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 1 (2024): January 2024 Issue
Abby S Van Voorhees, Sylvia Hsu, Boni Elewski, Shipra Rastogi, Robert J Israel, Efficacy and Safety of Brodalumab in Obese Patients with Moderate-to-Severe Plaque Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Neal Bhatia, MD, Jon Kantor, MD, Lawrence Green, MD, Jonathon Weiss, MD, Cynthia Wilson, RN, BSN, Susan Cutler, DMD, Jayson Rieger, PhD, MBA, David K. Glover, ME, PhD, Pamela Rumney, RN, CCRC, Gary Goldenberg, MD, Clinical and Histological Clearance of VP-315: Exploratory Results of an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Adelaide A Hebert, Dee Anna Glaser, Lawrence Green, William P Werschler, Douglass W Forsha, Janice Drew, Ramanan Gopalan, David M Pariser, Short- and Long-Term Efficacy and Safety of Glycopyrronium Cloth for the Treatment of Primary Axillary Hyperhidrosis: Post Hoc Pediatric Subgroup Analyses from the Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
Brad Glick, Edward Lain, Tina Lin, Robert Israel, Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast) , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Neal Bhatia, MD, Jonathon Kantor, MD, Lawrence Green, MD, Jonathon Weiss, MD, Cynthia Wilson, RN, BSN, Susan Cutler, DMD, Jayson Rieger, PhD, MBA, David K. Glover, ME, PhD, Pamela Rumney, RN, CCRC, Gary Goldenberg, MD, Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Julie Harper, Leon Kircik, Michael Gold, Adelaide Hebert, Jeffrey Sugarman, Lawrence Green, Linda Stein Gold, Hilary Baldwin, James Del Rosso, Eric Guenin , Early Acne Improvements With Fixed-Dose Clindamycin Phosphate 1.2%/ Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: What to Expect in the First 4 Weeks of Treatment , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 2 (2024): March 2024 Issue
Hee J Kim, Mark G Lebwohl, Combination of Calcipotriene Foam, 0.005% and Tazarotene Foam, 0.1% in the Treatment of Plaque Psoriasis of the Scalp and Body: A Case Report , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Steven R Feldman, Susan Harris, Shipra Rastogi, Robert J Israel, Distribution of Depression and Suicidality in a Psoriasis Clinical Trial Population , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Andrew F Alexis, Paul S Yamauchi, Tina Lin, Gina Martin, Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

<< < 1 2 3 4 5

Main Article Content

Keywords

Abstract

Article Sidebar

Article Details

Most read articles by the same author(s)